A double-blind, randomized, 4-period crossover study to evaluate the effect of ASP5633 on the opening urethral pressure (OUP) in healthy females

Trial Profile

A double-blind, randomized, 4-period crossover study to evaluate the effect of ASP5633 on the opening urethral pressure (OUP) in healthy females

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs ASP 5633 (Primary)
  • Indications Urinary incontinence
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 24 Oct 2016 New trial record
    • 16 Sep 2016 Results presented at the 46th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top